What are Appropriate End-points for Delirium Prevention/Treatment Studies

Transcription

1 What are Appropriate End-points for Delirium Prevention/Treatment Studies Pratik Pandharipande, MD, MSCI Professor of Anesthesiology and Surgery Department of Anesthesiology Vanderbilt University School of Medicine VA TN Valley Health Care System

2 Salary support Disclosure Vanderbilt Physician Scientist Award ( ) Foundation of Anesthesia Education and Research ( ) VA Career Development Award ( ) R01 NHLBI (HL111111) Research grant from Hospira Inc

3 Unique Challenges in Delirium Research Delirium is a syndrome with multiple risk factors Lack of consensus of what constitutes delirium Fluctuating course- potential for missing delirium Some delirium may resolve on its own irrespective of therapy Drop out/attrition Death, withdrawals, adverse events Problem not just an issue of sample size but more importantly about validity of data given missing outcome data

4 Common Delirium Specific Outcomes Delirium incidence/prevalence Delirium Duration Time to event- first episode of delirium or resolution of delirium Delirium-free days Delirium/Coma-free days

5 Common End of Trial Outcomes Incidence/Prevalence of Delirium Important from a patient perspective

6 Incidence/Prevalence or Duration of Delirium Limitations True incidence/prevalence missed due to fluctuation in mental status If fixed follow up period, delirium may be missed Treatment may not have enough time to impact outcome Issue in populations where the delirium is front loaded E.g. critically ill patients and many post-op patients

7

8 Risk of Developing Delirium in MENDS Pandharipande PP, et al. Critical Care. 2010, 14(2):R38)

9 Delirium Days Days p=.002 p=.50 Control Protocol Control Protocol Coma Delirium Girard TD, et al. Lancet 2008;371:126-34

10 Effect of Wake Up and Breathe on Coma Girard TD, et al. Unpublished data from the ABC Trial.

11 Effect of Wake Up and Breathe on Delirium Girard TD, et al. Unpublished data from the ABC Trial.

12 Time to Event Outcomes Time to first Episode of Delirium Time to Resolution of Delirium May have some real world benefit if it translates into faster MV liberation or shorter LOS

13 Time to Event Analysis Limitations Does not allow recurrence of criterion event What happens if you have resolution of delirium and then have delirium again What constitutes resolution of delirium? Addressing competing risks Early time to first episode of delirium may be a better option than being in a coma and not eligible for delirium assessment

14 Event-free Outcomes Delirium-free days Delirium-coma free days Attempt to account for confounding by death and coma

15 Event-free Outcomes 12 P=.01 P=.09 P= Dexmedetomidine Lorazepam Delirium/Coma-Free Days Delirium-Free Days Coma-Free Days Pandharipande PP, et al. JAMA. 2007;298:

16 Mortality (Short or long-term) While many prospective cohort studies have shown an association between delirium and mortality, no prevention/treatment trial of delirium has YET demonstrated any mortality benefit even when rates/duration of delirium were altered Is this because different delirium have different mortality risks and we are not targeting the right type of delirium? Is it because many patients do not consent/ or withdraw for interventional trials and those may have been the ones who were likely to have worse outcomes?

17 Outcome Daily Wake-Up + Early Mobility Intervention (n=49) Control (n=50) Functionally independent at discharge 29 (59%) 19 (35%).02 ICU delirium (days) 2.0 ( ) 4.0 ( ).03 Time in ICU with delirium (%) 33% (0-58) 57% (33-69).02 Hospital delirium (days) 2.0 ( ) 4.0 ( ).02 Hospital days with delirium (%) 28% (26) 41% (27).01 Barthel Index score at discharge 75 (7.5-95) 55 (0-85).05 ICU-acquired paresis at discharge 15 (31%) 27 (49%).09 Ventilator-free days 23.5 ( ) 21.1 ( ).05 Length of stay in ICU (days) 5.9 ( ) 7.9 ( ).08 Length of stay in hospital (days) 13.5 ( ) 12.9 ( ).93 Hospital mortality 9 (18%) 14 (25%).53 P Schweickert WD, et al. Lancet. 2009;373:

18 Long-term Cognitive Impairment Saczynski J et al..nejm 2012, 367 (1); 30-9

19

20 VANTAA 85+ Study Davis D. Brain 2012; 135;

21 Targeting Sub-groups for Mortality or LTCI outcomes Older patients Patients with mild cognitive impairment Patients with dementia or mental illnesses such as PTSD, depression Patients with frailty Patients who have higher severity of illness E.g. sepsis

22 Patients Alive (%) 28-Day Survival, Sepsis Patients: MENDS 100 Dexmedetomidine 80 Lorazepam HR=0.3 ( ); P= Days Pandharipande PP, et al. Critical Care. 2010, 14(2):R38)

23 Resource Utilization ICU and hospital lengths of stay Duration of mechanical ventilation Transfer to rehabilitation hospital Cost of care Care-giver burden Functional Outcomes Return to employment

24

25

26 Biomarkers and Delirium Identification of biomarkers associated with delirium and outcomes Effect of therapies on biomarker profile Studying the mediation effect of these biomarkers on the outcome of interest (delirium duration etc.) Statin Use and Risk of Delirium in the Critically Ill Valerie J Page, Daniel Davis et al. AJRCCM 2014 Statin administration the previous evening was associated with the patient being assessed as free of delirium (OR = 2.28, (CI 1.01 to 5.13) p < 0.05) and with lower CRP (β = -0.52, p <0.01) the following day. When the association between statin and being assessed as free of delirium was controlled for CRP, the effect size became non-significant (OR = 1.56, (CI 0.64 to 3.79) p=0.32).

27 Thank You!